|Day's Range||2.57 - 2.57|
|52 Week Range||1.93 - 7.85|
|PE Ratio (TTM)||-2.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
XTL Biopharmaceuticals Ltd. reports preliminary financial results for the quarter ended June 30, 2015.We analyze the earnings along side the following peers of XTL Biopharmaceuticals Ltd. Sponsored ADR – Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Anthera Pharmaceuticals, Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Astrazeneca PLC Sponsored ADR, Eli Lilly and Company, Teva […] (Read more...) The post XTL Biopharmaceuticals Ltd. Earnings Q2, 2015 appeared first on CapitalCube.
Among speculative small-cap biotechs, analyst calls are often accompanied with upside price targets of 50%, 100% or even 200%. This is because the companies are often all-in bets on one or two treatments....
In a report published Friday, analyst Swayampakula Ramakanth of HC Wainwright & Co initiated coverage of XTL Biopharmaceuticals Ltd (NASDAQ: XTLB ) with a Buy rating and a price target of $6. Of the three ...